Cyanin

Cyanin

SCHEMBL349836

OC[C@H]1OC(Oc2cc3c(OC4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)cc(O)cc3[o+]c2-c2ccc(O)c(O)c2)[C@H](O)[C@@H](O)[C@@H]1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 1/20 1.00
DPP4 P27487 1/20 0.89
CD38 P28907 1/20 0.89
KDM4E B2RXH2 4/20 0.49
GAA P10253 4/20 0.49
AKR1B1 P15121 4/20 0.49
MAPT P10636 3/20 0.49
POLB P06746 2/20 0.49
P4HB P07237 2/20 0.49
EPHX2 P34913 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
ADRA2C P18825 1/20 0.49
NOX4 Q9NPH5 1/20 0.49
CA12 O43570 1/20 0.49
KDM1A O60341 1/20 0.49
SLCO2B1 O94956 1/20 0.49
CA2 P00918 1/20 0.49
ALPL P05186 1/20 0.49
HMGB1 P09429 1/20 0.49
ALPI P09923 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cyanin SCHEMBL6139364 1.00 F2 (1.00) F2DPP4CD38KDM4EGAA
Cyanin SCHEMBL31019317 1.00 F2 (1.00) F2DPP4CD38KDM4EGAA
Cyanin SCHEMBL29453487 1.00 F2 (1.00) F2DPP4CD38KDM4EGAA
Cyanin SCHEMBL6138846 1.00 F2 (1.00) F2DPP4CD38KDM4EGAA
Cyanin SCHEMBL9234904 1.00 F2 (1.00) F2DPP4CD38KDM4EGAA
SCHEMBL6139043 1.00 F2 (1.00) F2DPP4CD38KDM4EGAA
Cyanin SCHEMBL29762024 0.99 F2 (0.98) F2DPP4CD38KDM4EGAA
SCHEMBL30217528 0.94 F2 (0.89) F2DPP4CD38KDM4EGAA
SCHEMBL4740208 0.94 F2 (0.89) F2DPP4CD38KDM4EGAA
Kuromanin SCHEMBL409593 0.94 CD38 (1.00) F2DPP4CD38KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025047832-A1 SKIN COSMETIC COMPOSITION CONTAINING BOTRYOCOCCENE AS ACTIVE INGREDIENT フィコケミー株式会社 2025-03-06 WO claimed
US-12011496-B2 Topical macqui berry formulation Tracie Martyn International, Inc. (US) 2024-06-18 US claimed
WO-2024118307-A1 TREATMENT OF AUTISM SPECTRUM DISORDERS WITH ERGOTHIONEINE, SELENONEINE, OR COMBINATIONS THEREOF Autism Therapeutics Inc. (US) 2024-06-06 WO claimed
WO-2023219526-A1 MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT PROKIN MILAN (RS) 2023-11-16 WO claimed
WO-2023167248-A1 NEW PEST CONTROL METHOD TARGETING RESPIRATORY ORGAN FORMING MECHANISM OF PESTS 国立研究開発法人産業技術総合研究所 2023-09-07 WO claimed
CN-115901991-A Extraction and determination method of anthocyanin in xylem of cinnabar plum stem 北京林业大学 2023-04-04 CN claimed
US-20220279829-A1 Use of Anthocyanin-Anionic Polysaccharide Complex for Preventing or Treating Influenza Virus A Infection JBKLAB CO., LTD. (KR) 2022-09-08 US claimed
US-20220249675-A1 Composition for Preventing, Ameliorating, or Treating Gastritis or peptic Ulcer Comprising Anthocyanin-Negatively Charged Polysaccharide Complex as Active Ingredient JBKLAB CO., LTD. (KR) 2022-08-11 US claimed
CN-114456218-A Blueberry anthocyanin, preparation method thereof and application of blueberry anthocyanin in preparation of functional food for resisting acrylamide neurotoxicity 中国农业大学 2022-05-10 CN claimed
US-20220105017-A1 TOPICAL MACQUI BERRY FORMULATION TRACIE MARTYN INT INC (US) 2022-04-07 US claimed
EP-1808169-A2 Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases Proteotech Inc. (US) 2007-07-18 EP claimed
US-6818234-B1 Dietary food supplement containing natural cyclooxygenase inhibitors and methods for inhibiting pain and inflammation ACCESS BUSINESS GROUP INTERNATIONAL LLC 2004-11-16 US claimed
US-20040152760-A1 Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases PROTAMED, INC. 2004-08-05 US claimed
JP-2003532634-A 2003-11-05 JP claimed
EP-1244435-A2 POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND $g(a)-SYNUCLEIN FIBRIL DISEASES Proteotech Inc. (US) 2002-10-02 EP claimed
WO-2002024212-A1 CHOLESTEROL IN BLOOD-LOWERING COMPOSITION AND ITS COMPLEX, AND METHOD FOR PREPARING THEM ULTIMATE LIFE TECHNOLOGY CO., LTD. (KR) 2002-03-28 WO claimed
US-20010047032-A1 Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases PROTAMED, INC. 2001-11-29 US claimed
WO-2001049281-A2 POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND α-SYNUCLEIN FIBRIL DISEASES PROTEOTECH, INC. (US) 2001-07-12 WO claimed
WO-1983001117-A1 FERTILITY INDICATOR SYSTEM CONTAINING ANTHOCYANIN PIGMENT GOLDMAN, DOROTHEE, F., E. 1983-03-31 WO claimed
US-4358288-A Fertility indicator system containing anthocyanin pigment GOLDMAN, DOROTHEE F.E. 1982-11-09 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010047032-A1 Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases SNCA, PARK7, HTT F2 4377/4885DPP4 3385/4885CD38 3135/4885
US-20040152760-A1 Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases SNCA, PARK7, HTT F2 4377/4885DPP4 3385/4885CD38 3135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.